Macquarie Group
TEVA icon

Macquarie Group’s Teva Pharmaceuticals TEVA Stock Holding History

Macquarie Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Buy
56,337
+5,998
+12% +$200K 0.01% 571
2026
Q1 		$1.52M Buy
50,339
+12,527
+33% +$403K 0.01% 580
2025
Q4 		$1.18M Sell
37,812
-14,741
-28% -$363K 0.01% 645
2025
Q3 		$1.06M Buy
52,553
+5,924
+13% +$104K ﹤0.01% 1309
2025
Q2 		$782K Hold
46,629
– – ﹤0.01% 1401
2025
Q1 		$717K Sell
46,629
-3,450
-7% -$61.6K ﹤0.01% 1435
2024
Q4 		$1.1M Buy
50,079
+4,415
+10% +$80.3K ﹤0.01% 1336
2024
Q3 		$823K Buy
45,664
+2,330
+5% +$40.8K ﹤0.01% 1411
2024
Q2 		$704K Sell
43,334
-741
-2% -$11.4K ﹤0.01% 1426
2024
Q1 		$622K Buy
44,075
+9,942
+29% +$125K ﹤0.01% 1423
2023
Q4 		$357K Buy
34,133
+786
+2% +$7.34K ﹤0.01% 1505
2023
Q3 		$340K Sell
33,347
-4,596
-12% -$42.8K ﹤0.01% 1476
2023
Q2 		$286K Sell
37,943
-5,197
-12% -$42.1K ﹤0.01% 1519
2023
Q1 		$382K Hold
43,140
– – ﹤0.01% 1494
2022
Q4 		$393K Buy
43,140
+6,483
+18% +$56.6K ﹤0.01% 1541
2022
Q3 		$296K Sell
36,657
-210
-0.6% -$1.86K ﹤0.01% 1580
2022
Q2 		$278K Sell
36,867
-8,243
-18% -$71.8K ﹤0.01% 1663
2022
Q1 		$424K Hold
45,110
– – ﹤0.01% 1684
2021
Q4 		$361K Sell
45,110
-55,760
-55% -$503K ﹤0.01% 1684
2021
Q3 		$982K Buy
100,870
+8,879
+10% +$83.1K ﹤0.01% 1591
2021
Q2 		$910K Sell
91,991
-15,463
-14% -$164K ﹤0.01% 1613
2021
Q1 		$1.24M Hold
107,454
– – ﹤0.01% 1339
2020
Q4 		$1.04M Sell
107,454
-501,700
-82% -$4.81M ﹤0.01% 1305
2020
Q3 		$5.49M Buy
609,154
+49,726
+9% +$526K 0.01% 807
2020
Q2 		$6.9M Sell
559,428
-1,463,872
-72% -$16.6M 0.01% 717
2020
Q1 		$18.2M Hold
2,023,300
– – 0.04% 437
2019
Q4 		$19.8M Buy
2,023,300
+16,400
+0.8% +$146K 0.03% 519
2019
Q3 		$13.8M Hold
2,006,900
– – 0.02% 534
2019
Q2 		$18.5M Buy
2,006,900
+530,000
+36% +$6.39M 0.03% 477
2019
Q1 		$23.2M Buy
1,476,900
+1,445,400
+4,589% +$25.5M 0.04% 423
2018
Q4 		$485K Sell
31,500
-700
-2% -$14.4K ﹤0.01% 1293
2018
Q3 		$693K Sell
32,200
-102,700
-76% -$2.38M ﹤0.01% 1265
2018
Q2 		$3.28M Sell
134,900
-23,000
-15% -$469K 0.01% 865
2018
Q1 		$2.7M Sell
157,900
-4,800
-3% -$93.7K ﹤0.01% 908
2017
Q4 		$3.67M Sell
162,700
-4,245,631
-96% -$63.9M 0.01% 858
2017
Q3 		$77.6M Buy
4,408,331
+3,429,448
+350% +$77.2M 0.14% 129
2017
Q2 		$32.5M Buy
978,883
+43,757
+5% +$1.35M 0.06% 313
2017
Q1 		$30M Buy
935,126
+15,153
+2% +$517K 0.05% 337
2016
Q4 		$33.3M Buy
919,973
+29,770
+3% +$1.19M 0.06% 281
2016
Q3 		$41M Sell
890,203
-89,843
-9% -$4.69M 0.08% 221
2016
Q2 		$49.2M Sell
980,046
-291,972
-23% -$15.5M 0.1% 167
2016
Q1 		$68.1M Sell
1,272,018
-739,908
-37% -$43.4M 0.14% 120
2015
Q4 		$132M Sell
2,011,926
-1,476,924
-42% -$91.3M 0.27% 72
2015
Q3 		$197M Sell
3,488,850
-1,261,907
-27% -$81.8M 0.42% 58
2015
Q2 		$281M Sell
4,750,757
-762,169
-14% -$47M 0.56% 48
2015
Q1 		$343M Sell
5,512,926
-1,922,569
-26% -$112M 0.67% 40
2014
Q4 		$428M Sell
7,435,495
-789,346
-10% -$44M 0.88% 36
2014
Q3 		$442M Buy
8,224,841
+72,645
+0.9% +$3.85M 0.95% 37
2014
Q2 		$427M Sell
8,152,196
-612,105
-7% -$31.3M 0.95% 31
2014
Q1 		$463M Sell
8,764,301
-1,488,238
-15% -$68.8M 0.8% 27
2013
Q4 		$411M Buy
10,252,539
+1,118,270
+12% +$44M 0.74% 42
2013
Q3 		$345M Buy
9,134,269
+1,449,823
+19% +$56.6M 0.67% 54
2013
Q2 		$301M Buy
+7,684,446
New +$299M 0.66% 60

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Macquarie Group's TEVA Position: Q2 2026 in Review

Macquarie Group increased its Teva Pharmaceuticals (TEVA) stake by 12% in Q2 2026, buying an estimated $200K and bringing the position to 56,337 shares worth $1.91M. The position accounts for 0.01% of the portfolio, ranked #571.

Macquarie Group first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $463M in Q1 2014. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Macquarie Group held 56,337 shares of Teva Pharmaceuticals worth $1.91M as of Q2 2026.
  • Macquarie Group bought 5,998 Teva Pharmaceuticals shares in Q2 2026, an estimated $200K.
  • Teva Pharmaceuticals made up 0.01% of Macquarie Group's portfolio in Q2 2026, its #571 holding.
  • Macquarie Group first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Macquarie Group's Teva Pharmaceuticals position peaked at $463M in Q1 2014.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.